We are supported by
We are advancing a lead programme in second-line and later metastatic colorectal cancer, with a tumour-agnostic engine designed to extend the same platform to further solid tumours over time. We are also working on tumour-specific assets for harder-to-treat cases, and an in-vivo programme to enable public-healthcare access where autologous therapy cost may be prohibitive.
All programmes are pre-clinical. Stage labels describe current focus and planned sequence; they are not claims of clinical progress or timing.
Programme identifiers are illustrative placeholders. Stage positions reflect current research focus, not regulatory milestones.
The lead programme proves the platform on a defined indication. Because the navigation engine is designed to be tumour-agnostic, the same systems are intended to extend to further solid tumours — sequenced by evidence, not ambition.
mCRC 2L+ — the proving ground for the full integrated construct.
Candidates where the same recognition and navigation logic is expected to apply.
The STNAV engine carried across programmes rather than rebuilt each time.
Each expansion step advances only when its readout bar is cleared.
We are supported by